Perspective Therapeutics (CATX) Net Margin (2010 - 2023)

Perspective Therapeutics has disclosed Net Margin across 14 years of filings, most recently posting 105.73% for Q4 2023.

• Net Margin for Q4 2023 came in at 105.73%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 1476.84% (changed N/A YoY), and the FY2023 annual result was 631.31%, changed N/A from the prior year.
• Net Margin came in at 105.73% for Q4 2023 at Perspective Therapeutics, up from 35.88% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 105.73% in Q4 2023 to a low of 236.92% in Q3 2022.
• The 5-year median for Net Margin is 46.29% (2022), against an average of 54.04%.
• Across the five-year window, Net Margin sank 14944 bps in 2022 and surged 20104 bps in 2023, its largest moves.
• Perspective Therapeutics' Net Margin stood at 40.75% in 2019, then climbed by 10 bps to 36.8% in 2020, then tumbled by 55 bps to 56.96% in 2021, then plunged by 316 bps to 236.92% in 2022, then surged by 145 bps to 105.73% in 2023.
• The last three Net Margin figures came in at 105.73% (Q4 2023), 35.88% (Q3 2023), and 108.0% (Q2 2023), per Business Quant data.